Venlafaxine and bladder function

Maurizio Inghilleri, A. Conte, V. Frasca, C. Marini Bettolo, E. Iacovelli, M. Aragona, A. Carbone, M. Prencipe

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Occasional case reports describe urinary incontinence in patients taking the selective serotonin and norepinephrine reuptake inhibitor antidepressant venlafaxine. OBJECTIVE: In this study the authors investigated the possible effect of venlafaxine on urinary function in a series of 9 patients with urinary retention resulting from spinal cord lesions. They primarily sought to understand whether the reported venlafaxine-induced urinary incontinence was a specific drug-induced effect and, if so, whether venlafaxine might be an effective treatment of urinary retention. METHODS: During a 1-week baseline period, patients measured postvoiding residual volume through a catheter and recorded the number of micturitions within 24 hours. At the end of the baseline period, venlafaxine 75 mg extended-release on a once-daily evening administration schedule was added to their therapy for 1 week. RESULTS: None of the patients reported severe/uncontrollable side effects while taking venlafaxine. Extended-release venlafaxine (75 mg/day) significantly reduced the postvoiding residual volume and increased the micturition rate; the volume diminished on the first day of treatment and remained stable over the ensuing days. CONCLUSION: These findings suggest that venlafaxine could be useful to improve voiding in patients with spinal cord disease.

Original languageEnglish
Pages (from-to)270-273
Number of pages4
JournalClinical Neuropharmacology
Volume28
Issue number6
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Urinary Bladder
Residual Volume
Urinary Retention
Urination
Urinary Incontinence
Venlafaxine Hydrochloride
Spinal Cord Diseases
Serotonin Uptake Inhibitors
Antidepressive Agents
Spinal Cord
Appointments and Schedules
Therapeutics
Catheters
Pharmaceutical Preparations

Keywords

  • Postvoiding residual volume
  • SNRI
  • Venlafaxine
  • Vesicosphincteric dyssynergia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Inghilleri, M., Conte, A., Frasca, V., Bettolo, C. M., Iacovelli, E., Aragona, M., ... Prencipe, M. (2005). Venlafaxine and bladder function. Clinical Neuropharmacology, 28(6), 270-273. https://doi.org/10.1097/01.wnf.0000191353.40812.b4

Venlafaxine and bladder function. / Inghilleri, Maurizio; Conte, A.; Frasca, V.; Bettolo, C. Marini; Iacovelli, E.; Aragona, M.; Carbone, A.; Prencipe, M.

In: Clinical Neuropharmacology, Vol. 28, No. 6, 11.2005, p. 270-273.

Research output: Contribution to journalArticle

Inghilleri, M, Conte, A, Frasca, V, Bettolo, CM, Iacovelli, E, Aragona, M, Carbone, A & Prencipe, M 2005, 'Venlafaxine and bladder function', Clinical Neuropharmacology, vol. 28, no. 6, pp. 270-273. https://doi.org/10.1097/01.wnf.0000191353.40812.b4
Inghilleri M, Conte A, Frasca V, Bettolo CM, Iacovelli E, Aragona M et al. Venlafaxine and bladder function. Clinical Neuropharmacology. 2005 Nov;28(6):270-273. https://doi.org/10.1097/01.wnf.0000191353.40812.b4
Inghilleri, Maurizio ; Conte, A. ; Frasca, V. ; Bettolo, C. Marini ; Iacovelli, E. ; Aragona, M. ; Carbone, A. ; Prencipe, M. / Venlafaxine and bladder function. In: Clinical Neuropharmacology. 2005 ; Vol. 28, No. 6. pp. 270-273.
@article{dd5aee88b81d48bc8a233692fa4b58a2,
title = "Venlafaxine and bladder function",
abstract = "BACKGROUND: Occasional case reports describe urinary incontinence in patients taking the selective serotonin and norepinephrine reuptake inhibitor antidepressant venlafaxine. OBJECTIVE: In this study the authors investigated the possible effect of venlafaxine on urinary function in a series of 9 patients with urinary retention resulting from spinal cord lesions. They primarily sought to understand whether the reported venlafaxine-induced urinary incontinence was a specific drug-induced effect and, if so, whether venlafaxine might be an effective treatment of urinary retention. METHODS: During a 1-week baseline period, patients measured postvoiding residual volume through a catheter and recorded the number of micturitions within 24 hours. At the end of the baseline period, venlafaxine 75 mg extended-release on a once-daily evening administration schedule was added to their therapy for 1 week. RESULTS: None of the patients reported severe/uncontrollable side effects while taking venlafaxine. Extended-release venlafaxine (75 mg/day) significantly reduced the postvoiding residual volume and increased the micturition rate; the volume diminished on the first day of treatment and remained stable over the ensuing days. CONCLUSION: These findings suggest that venlafaxine could be useful to improve voiding in patients with spinal cord disease.",
keywords = "Postvoiding residual volume, SNRI, Venlafaxine, Vesicosphincteric dyssynergia",
author = "Maurizio Inghilleri and A. Conte and V. Frasca and Bettolo, {C. Marini} and E. Iacovelli and M. Aragona and A. Carbone and M. Prencipe",
year = "2005",
month = "11",
doi = "10.1097/01.wnf.0000191353.40812.b4",
language = "English",
volume = "28",
pages = "270--273",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Venlafaxine and bladder function

AU - Inghilleri, Maurizio

AU - Conte, A.

AU - Frasca, V.

AU - Bettolo, C. Marini

AU - Iacovelli, E.

AU - Aragona, M.

AU - Carbone, A.

AU - Prencipe, M.

PY - 2005/11

Y1 - 2005/11

N2 - BACKGROUND: Occasional case reports describe urinary incontinence in patients taking the selective serotonin and norepinephrine reuptake inhibitor antidepressant venlafaxine. OBJECTIVE: In this study the authors investigated the possible effect of venlafaxine on urinary function in a series of 9 patients with urinary retention resulting from spinal cord lesions. They primarily sought to understand whether the reported venlafaxine-induced urinary incontinence was a specific drug-induced effect and, if so, whether venlafaxine might be an effective treatment of urinary retention. METHODS: During a 1-week baseline period, patients measured postvoiding residual volume through a catheter and recorded the number of micturitions within 24 hours. At the end of the baseline period, venlafaxine 75 mg extended-release on a once-daily evening administration schedule was added to their therapy for 1 week. RESULTS: None of the patients reported severe/uncontrollable side effects while taking venlafaxine. Extended-release venlafaxine (75 mg/day) significantly reduced the postvoiding residual volume and increased the micturition rate; the volume diminished on the first day of treatment and remained stable over the ensuing days. CONCLUSION: These findings suggest that venlafaxine could be useful to improve voiding in patients with spinal cord disease.

AB - BACKGROUND: Occasional case reports describe urinary incontinence in patients taking the selective serotonin and norepinephrine reuptake inhibitor antidepressant venlafaxine. OBJECTIVE: In this study the authors investigated the possible effect of venlafaxine on urinary function in a series of 9 patients with urinary retention resulting from spinal cord lesions. They primarily sought to understand whether the reported venlafaxine-induced urinary incontinence was a specific drug-induced effect and, if so, whether venlafaxine might be an effective treatment of urinary retention. METHODS: During a 1-week baseline period, patients measured postvoiding residual volume through a catheter and recorded the number of micturitions within 24 hours. At the end of the baseline period, venlafaxine 75 mg extended-release on a once-daily evening administration schedule was added to their therapy for 1 week. RESULTS: None of the patients reported severe/uncontrollable side effects while taking venlafaxine. Extended-release venlafaxine (75 mg/day) significantly reduced the postvoiding residual volume and increased the micturition rate; the volume diminished on the first day of treatment and remained stable over the ensuing days. CONCLUSION: These findings suggest that venlafaxine could be useful to improve voiding in patients with spinal cord disease.

KW - Postvoiding residual volume

KW - SNRI

KW - Venlafaxine

KW - Vesicosphincteric dyssynergia

UR - http://www.scopus.com/inward/record.url?scp=33644875312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644875312&partnerID=8YFLogxK

U2 - 10.1097/01.wnf.0000191353.40812.b4

DO - 10.1097/01.wnf.0000191353.40812.b4

M3 - Article

C2 - 16340381

AN - SCOPUS:33644875312

VL - 28

SP - 270

EP - 273

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 6

ER -